Branded Legacy, Inc. Strengthens Biotech Leadership, Focuses on Expansion, and Advances Strategic Rebranding
Branded Legacy (OTC.PK: BLEG) faces significant challenges including a cyber attack by former employees that disrupted operations and reduced projected revenue from a $10M contract. The company has restructured by releasing several subsidiaries and is now focusing on its Sycamore BioPharma division.
The company plans to sell MariJ Pharmaceuticals to offset dilution and will increase authorized shares to fund operations. BLEG is in discussions to supply one-fifth of Europe's CBD market, targeting production of 3 tons of CBD isolate monthly. The company is also rebranding to Royal Enterprises.
Branded Legacy (OTC.PK: BLEG) affronta sfide significative, inclusi un attacco informatico da parte di ex dipendenti che ha interrotto le operazioni e ridotto il fatturato previsto da un contratto di 10 milioni di dollari. L'azienda si è ristrutturata liberando diverse filiali e ora si concentra sulla sua divisione Sycamore BioPharma.
L'azienda prevede di vendere MariJ Pharmaceuticals per compensare la diluizione e aumenterà le azioni autorizzate per finanziare le operazioni. BLEG è in trattative per fornire un quinto del mercato europeo del CBD, puntando a una produzione mensile di 3 tonnellate di isolato di CBD. L'azienda sta anche cambiando nome in Royal Enterprises.
Branded Legacy (OTC.PK: BLEG) enfrenta desafíos significativos, incluido un ciberataque por parte de antiguos empleados que interrumpió las operaciones y redujo los ingresos proyectados de un contrato de 10 millones de dólares. La compañía se ha reestructurado al liberar varias subsidiarias y ahora se está enfocando en su división Sycamore BioPharma.
La compañía planea vender MariJ Pharmaceuticals para compensar la dilución y aumentará las acciones autorizadas para financiar las operaciones. BLEG está en negociaciones para suministrar una quinta parte del mercado europeo de CBD, con el objetivo de producir 3 toneladas de aislado de CBD mensualmente. La empresa también se está rebranding como Royal Enterprises.
Branded Legacy (OTC.PK: BLEG)는 전 직원의 사이버 공격으로 인해 운영이 중단되고 1천만 달러 계약에서 예상 수익이 감소하는 등 상당한 도전에 직면해 있습니다. 회사는 여러 자회사를 정리하여 구조 조정을 하였으며, 이제 시카모어 바이오파마 부문에 집중하고 있습니다.
회사는 희석화를 상쇄하기 위해 MariJ Pharmaceuticals를 판매할 계획이며, 운영 자금을 마련하기 위해 승인된 주식을 늘릴 것입니다. BLEG는 유럽 CBD 시장의 5분의 1을 공급하기 위해 논의 중이며, 매월 3톤의 CBD 분리를 생산할 계획입니다. 또한 회사는 로열 엔터프라이즈로 브랜드를 변경하고 있습니다.
Branded Legacy (OTC.PK: BLEG) fait face à des défis importants, notamment une cyberattaque d'anciens employés qui a perturbé les opérations et réduit les revenus projetés d'un contrat de 10 millions de dollars. L'entreprise s'est restructurée en se séparant de plusieurs filiales et se concentre désormais sur sa division Sycamore BioPharma.
L'entreprise prévoit de vendre MariJ Pharmaceuticals pour compenser la dilution et augmentera les actions autorisées pour financer ses opérations. BLEG est en discussion pour fournir un cinquième du marché européen du CBD, visant une production de 3 tonnes d'isolat de CBD par mois. L'entreprise se renomme également Royal Enterprises.
Branded Legacy (OTC.PK: BLEG) sieht sich erheblichen Herausforderungen gegenüber, darunter ein Cyberangriff ehemaliger Mitarbeiter, der die Betriebsabläufe gestört und den prognostizierten Umsatz aus einem Vertrag über 10 Millionen Dollar reduziert hat. Das Unternehmen hat sich neu strukturiert, indem es mehrere Tochtergesellschaften aufgegeben hat, und konzentriert sich nun auf seine Sycamore BioPharma-Abteilung.
Das Unternehmen plant, MariJ Pharmaceuticals zu verkaufen, um die Verwässerung auszugleichen, und wird die genehmigten Aktien erhöhen, um die Betriebsabläufe zu finanzieren. BLEG befindet sich in Gesprächen, um ein Fünftel des europäischen CBD-Marktes zu beliefern, mit dem Ziel, monatlich 3 Tonnen CBD-Isolat zu produzieren. Das Unternehmen führt auch eine Umbenennung in Royal Enterprises durch.
- Potential major CBD supply agreement targeting 3 tons monthly production
- Strategic restructuring to focus on core biotech subsidiary Sycamore BioPharma
- Planned sale of MariJ Pharmaceuticals to generate funding
- Cyber attack compromised digital assets and banking access
- Loss of significant revenue from $10M contract
- Planned share dilution through increased authorized shares
- Operational disruptions from hurricane and shipping delays
- Multiple subsidiary divestments indicating business contraction
Company Refocuses on Sycamore BioPharma, Navigates Challenges, and Prepares for Rebranding to Royal Enterprises, Inc
ORLANDO, Fla., Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc (OTC.PK: BLEG), provides updates as it confronts recent challenges and charts a focused path forward. The company has reaffirmed its commitment to the biotech and wellness sectors, with its primary focus now on expanding its wholly owned subsidiary, Sycamore BioPharma.
Addressing Recent Challenges
Branded Legacy recently endured a targeted attack that temporarily compromised its digital assets, including critical platforms such as banking and OTC accounts access. This malicious act, orchestrated in part by former employees, not only disrupted operations but also resulted in delays and reduction of profit from a major contract projected to generate over
In response, Branded Legacy has taken decisive action to secure its digital assets, remove individuals involved in the attack, and restructure its operations. Released subsidiaries include The Alcannabist LLC, Rocket Web Development and Design LLC, and All In Extracts LLC. All executives associated with these subsidiaries have been removed from their positions and are no longer associated with the company. Branded Legacy is now focused on overcoming these setbacks by concentrating its efforts and resources on Sycamore BioPharma, its flagship subsidiary.
Strategic Focus on Sycamore BioPharma
Sycamore BioPharma, acquired by Branded Legacy eight months ago, has become the cornerstone of the company's growth strategy. Renowned for its development of innovative wellness solutions, Sycamore BioPharma aligns seamlessly with Branded Legacy's commitment to quality, natural ingredients, and scientific excellence. With a focus on expanding Sycamore's operations and pipeline, Branded Legacy is positioning itself to capture new market opportunities and drive long-term success.
To support this renewed focus, Branded Legacy has entered discussions for the sale of MariJ Pharmaceuticals Inc. Revenue from this sale will be used to offset dilution moving forward, as we fund Sycamore's continued development and operational expansion. Additionally, we have determined that a raise of the authorized share count will be necessary to offset any funding gaps from the MariJ sale. This will ensure the company can execute its strategic objectives, recover from the impact of lost revenue, and pursue new growth opportunities in the biotech and wellness markets.
Looking to the Future
Despite recent setbacks, Branded Legacy remains steadfast in its mission. The company is advancing late-stage discussions to supply one-fifth of Europe's CBD market, an initiative that could significantly expand its international footprint. Our specific goal is to scale up to production of 3 tons of CBD isolate monthly, with 1.5 tons being exported to the European Union and 1.5 tons sold domestically through existing channels. In addition, the company is moving forward with its rebranding initiative, transitioning its name and symbol to Royal Enterprises, Inc. (ROYL) to reflect its evolution and renewed focus.
"These challenges have only strengthened our resolve," stated CEO Dave Oswald. "While the actions of former employees have created significant hurdles, our commitment to growth and innovation remains unwavering. By focusing on our more successful subsidiaries and securing the necessary funding to expand, we are poised to recover and achieve even greater success in the biotech and wellness industries. Concerning our share structure and other changes: We made our best effort to keep a tight share structure, and support share price growth as much as possible to attract investors. However, after nearly 2 years, it is time to accept that the market reaction was not what we had hoped. At this point it has become necessary for us to utilize the public vehicle in such a way that it directly benefits the company's operations. Previously I have stated that we would not be raising the authorized any time soon. Unfortunately, I did not foresee our current predicaments, and I have to admit that I was wrong. While efforts will still be made to protect and grow the SP, all options will be on the table moving forward. Specifically, we will be raising the authorized to compensate our remaining executives, support acquisitions, and seek additional capital for expansion."
About Branded Legacy:
Branded Legacy, Inc. is a forward-thinking company specializing in the development and commercialization of biotech and wellness products. With a focus on strategic growth, innovation, and quality, the company is dedicated to enhancing lives and creating sustainable value for its shareholders.
Media Contact
Media at Branded Legacy
Phone: (321) 345-3565
Email: info@brandedlegacy.com
Website: https://brandedlegacy.com/
Safe Harbor Statement on Forward-Looking Language:
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
FAQ
What caused the recent operational disruptions at Branded Legacy (BLEG)?
What is Branded Legacy's (BLEG) new business focus?
What is Branded Legacy's (BLEG) European CBD market plan?
What is Branded Legacy's (BLEG) new company name?
